Bulbospinal Muscular Atrophy Drugs Market 2019 Increasing Healthcare Expenditure With Leadiant Biosciences, Inc, Abbott, Novo Nordisk A/S, AstraZeneca
The global bulbospinal muscular atrophy drugs market is growing at a steady CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the granting of various drug designations to novel drugs by the U.S FDA, initiatives are undertaken by various public, as well as nonprofit, organizations for creating awareness regarding bulbospinal muscular atrophy and increase in R&D investment by major companies.
Get Exclusive Sample PDF of Report at https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market
The key market players in the global bulbospinal muscular atrophy drugs market are
F. Hoffmann-La Roche Ltd,
Boehringer Ingelheim International GmbH,
Ionis Pharmaceuticals, Inc,
Regeneron Pharmaceuticals, Inc,
Salarius Pharmaceuticals, Inc,
Leadiant Biosciences, Inc,
Novo Nordisk A/S,
Takeda Pharmaceutical Company Limited,
Natera, Inc among others
Global Bulbospinal Muscular Atrophy Drugs Market By Drugs Class (5α-Reductase Inhibitors (5-ARIs), Gonadotropin-releasing Hormone (GnRH) Agonists and Others), Drugs (Leuprorelin, Dutasteride and Others), Therapy (Physical Therapy, Occupational Therapy, and Speech Therapy), Treatment (Medication, Supportive Care and Surgery), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2026
Bulbospinal muscular atrophy is also known as Kennedy’s disease, a rare adult-onset form of spinal muscular atrophy (SMA) is an X-linked autosomal recessive progressive neurodegenerative disorder that causes weakening and wasting of the proximal and bulbar muscles. The condition occurs due to loss of nerve cells in the brain stem and spinal cord, this result in stoppage of messages from brain to muscles for movement. Patients with bulbospinal muscular atrophy have difficulty in speaking, standing, walking and controlling their head movements. In worse condition patients can have trouble swallowing and breathing. This disorder mainly affects men and does not occur in females, who are protected by their low levels of testosterone in the body, accounting for the sex-limited inheritance pattern of this disorder.
According to National Organization for Rare Disorders, Bulbospinal muscular atrophy or Kennedy disease is a very rare type of disorder and it affects 1 in 350,000 males and rarely seen in females. The Japanese population has a very high prevalence of this disorder because of a founder effect.
Growing number of incidences of spinal bulbar muscular atrophy is driving the growth of the market
Initiatives undertaken by various public, as well as nonprofit, organizations for creating awareness regarding bulbospinal muscular atrophy also acts as a market driver
Increase in R&D investment by major companies is boosting the market growth
Increasing healthcare expenditure can also enhance the market growth
High cost of treatment for bulbospinal muscular atrophy is hindering the market growth
Lack of experienced professionals in this field can also act as a restricting factor for the growth of this market
Limited number of drugs available for bulbospinal muscular atrophy treatment also hampers the market growth
Order a Copy of Global Bulbospinal Muscular Atrophy Drugs Market Report at https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market
Segmentation: Global Bulbospinal Muscular Atrophy Drugs Market
By Drugs Class
5α-Reductase Inhibitors (5-ARIs)
Gonadotropin-releasing Hormone (GnRH) Agonists
By Route of Administration
By Distribution Channel
Middle East & Africa
Key Developments in the Market
In April 2019, Novartis AG is developing BVS857, a novel drug for the treatment of bulbospinal muscular atrophy, currently ongoing in phase ll clinical trial. If approved this novel drug will provide a potential treatment for patients with bulbospinal muscular atrophy and help in improving their life
In August 2018, Takeda Pharmaceutical Company Limited is developing Leuprorelin, a gonadotropin-releasing hormone (GnRH) agonist for the treatment of bulbospinal muscular atrophy. If approved this drug will provide a potential treatment for patients with bulbospinal muscular atrophy
Global bulbospinal muscular atrophy drugs market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of bulbospinal muscular atrophy drugs market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Reasons to Purchase this Report:
Current and future of global bulbospinal muscular atrophy drugs market outlook in the developed and emerging markets.
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/Countries that are expected to witness the fastest growth rates during the forecast period.
The latest developments, market shares, and strategies that are employed by the major market players.
Table of Contents:
2. Market Segmentation
3. Market Overview
4. Executive Summary
5. Premium Insights
6. Global, By Component
7. Product Type
9. Industry Type
10.2. North America
10.5. South America
10.6. Middle East & Africa
11. Company Landscape
12. Company Profiles
13. Related Reports
Access Detailed TOC at https://www.databridgemarketresearch.com/toc/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
About Data Bridge Market Research
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bulbospinal Muscular Atrophy Drugs Market 2019 Increasing Healthcare Expenditure With Leadiant Biosciences, Inc, Abbott, Novo Nordisk A/S, AstraZeneca here
News-ID: 1867150 • Views: 293
More Releases from Data Bridge Market Research
Electronic Adhesives Market to set Phenomenal Growth| Bondline Electronic Adhesi …
The Global Electronic Adhesives Market report provides an unbiased and detailed analysis of the on-going trends, opportunities/ high growth areas, market drivers, which would help stakeholders to device and align Electronic Adhesives market strategies according to the current and future market. The Electronic Adhesives Market report covers the Global market and regional market analysis. The industry report examines, keep records and presents the worldwide market size of the important players
Construction Equipment Market to set Phenomenal Growth| AB Volvo, Komatsu, Hyund …
The Global Construction Equipment Market report provides an unbiased and detailed analysis of the on-going trends, opportunities/ high growth areas, market drivers, which would help stakeholders to device and align Construction Equipment market strategies according to the current and future market. The Construction Equipment Market report covers the Global market and regional market analysis. The industry report examines, keep records and presents the worldwide market size of the important players
Carpets and Rugs Market Impressive Growth| Tarkett, Inter IKEA Systems, Interfac …
The Global Carpets and Rugs Market report provides an unbiased and detailed analysis of the on-going trends, opportunities/ high growth areas, market drivers, which would help stakeholders to device and align Carpets and Rugs market strategies according to the current and future market. The Carpets and Rugs Market report covers the Global market and regional market analysis. The industry report examines, keep records and presents the worldwide market size of
Seafood Processing Equipment Market Status Analysis and Forecast 2026 By ARCOS L …
Global Seafood Processing Equipment Market is expected to rise from its initial estimated value of USD 2.03 billion in 2018 to an estimated value of USD 2.68 billion by 2026, registering a CAGR of 3.51% in the forecast period of 2019-2026. Increase in the demand for the healthy food is the major factor for the growth of this market. seafood processing equipment market report comprises of historic data along with future
More Releases for Drugs
Global Cardiovascular Drugs Market
Global Cardiovascular Drugs Market – Industry Analysis and Forecast (2018-2026) – by Drug Class, Indications, Distribution Channels, and Region. Global Cardiovascular Drugs Market was valued at US$ 80.5 Bn in 2017 and is expected to reach US$ 98.8 Bn by 2026, at a CAGR of 2.6 % during the forecast period. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data,
Cardiovascular Drugs Market | Insights
Some of the common cardiovascular diseases include hypertensive heart disease, rheumatic heart disease, ischemic heart disease, inflammatory heart disease, and cerebrovascular heart disease. Major problems associated with hypertensive heart disease include angina, hypertrophy, and heart failure. These problems are caused due to high blood pressure in the heart’s arteries and muscles, which causes narrowing of arteries and thickening and enlargement of heart. The global cardiovascular drug market is primarily driven
Immunotherapy Drugs Market
Immunotherapy drugs are used to treat cancer, infection, respiratory and autoimmune disorders. Immunotherapies either stimulate the activities done by specific components of the immune system or counteract the signals that are produced by the cancer cells and suppress the immune responses. The Immunotherapy Drugs Market accounted to USD 107 billion in 2016 growing at a CAGR of 13.2% during the forecast period of 2017 to 2024. The upcoming market report contains
Immunotherapy Drugs Market
Immunotherapy is the management of a disease by enhancing, suppressing, or inducing an immune response. Some immunotherapies are designed to magnify or elicit an immune response. They are known as activation immunotherapies. However, some immunotherapies that suppress or reduce the immune response are known as suppression immunotherapies. Cell-based immunotherapies are useful for some types of cancers. Immune effector cells includingmacrophages, dendritic cells, lymphocytes, cytotoxic T lymphocytes (CTL), natural killer cells
Tardive Dyskinesia Drugs Market
Tardive dyskinesia (TD) is a form of dyskinesia that is difficult to treat. It is a nerve disorder characterized by involuntary movements such as jaw, lips, and tongue, considered as grimacing, sticking the tongue out, and lip smacking. Some other symptoms are an individual experiencing involuntary movement of the lower and upper extremities and also breathing choking. According to Center for Drug Evaluation and Research, tardive dyskinesia can lead to
Erythropoietin Drugs Market
Erythropoietin alfa is widely used to treat anemia and increase the red blood cells count in the body. Erythropoietin drugs are developed in vitro by extracting the erythropoietin from the human body and developing it through the use of recombinant DNA technology. Erythropoietin drugs are also used to treat anemia induced from cancer, multiple myloma and HIV associated anemia. Recombinant DNA technology has allowed researchers to develop synthetic forms of